This podcast episode underscores the ethical considerations surrounding ketogenic diets and their potential impact on cardiovascular health, particularly regarding ApoB levels, a critical marker for atherosclerotic cardiovascular disease. Dr. Thomas Dayspring leads an insightful discussion on the significance of both lifestyle and pharmacotherapy in managing lipid levels, delving into various lipid-lowering interventions—from statins and PCSK9 inhibitors to emerging gene therapies. The dialogue emphasizes the limitations of solely focusing on HDL and triglycerides, advocating for a more comprehensive lipid management strategy that prioritizes ApoB levels to effectively reduce cardiovascular risk.
